Considering first therapeutic approaches, a FAT1-derived epitope was successfully tested as anti-CRC cancer vaccine in a murine model and therapeutic antibodies or antibody-conjugated drugs directed against FAT1 for CRC are under development, mechanistically applicable also for T-ALL40–42. Here, FAT1 is linked to colorectal carcinoma.